Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter phase 4 study of high-dose retreatment regimens for pulmonary tuberculosis
ChiCTR1900021587Phase 4Not yet recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Jan 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of isoniazid, rifampicin, ethambutol, pyrazinamide, levofloxacin and 5 more in pulmonary tuberculosis (TB) (6 arms), sponsored by Beijing Chest Hospital. Primary endpoints: cure rate, default rate and 3 more. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
isoniazidrifampicinethambutolpyrazinamidelevofloxacin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR1900021587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021587.